Biotron Limited (AU:BIT) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Biotron Limited reported mixed results from its Phase 2 COVID-19 trial for the antiviral drug BIT225, which met safety and tolerability endpoints but not efficacy targets. Despite this, Biotron continues to advance its research on antiviral compounds, including promising developments in HIV-1 and Dengue virus programs. The company remains committed to exploring commercial opportunities for its unique viroporin antagonist platform, which shows broad-spectrum antiviral activity.
For further insights into AU:BIT stock, check out TipRanks’ Stock Analysis page.
